H1 2026 Trading Update
Summary by AI BETAClose X
EKF Diagnostics Holdings plc
("EKF" or the "Company")
H1 2026 Trading Update
Continued improvement in earnings and cash generation
EKF Diagnostics Holdings plc (AIM: EKF), the AIM-quoted global diagnostics business, provides the following unaudited trading update for the six months ended 30 June 2026 ("H1 2026").
Trading during the period was in line with management expectations, with improved gross margin, growth in adjusted EBITDA and continued cash generation.
Revenue for H1 2026 remained broadly flat at £25.0m (H1 2025: £25.2m), reflecting the higher weighting of sales expected in the second half of the year. Gross margin improved to 53% (H1 2025: 50%) and adjusted EBITDA1 showed continued growth.
The Group's cash balance as at 30 June 2026 was £16.0m (31 December 2025: £15.8m), which included £2.4m held in Russia (31 December 2025: £2.1m). The Company has no bank borrowings, and the closing cash balance reflects the allocation of £1.4m for the ongoing share buyback programme, of which £0.9m has been deployed during the period, together with the continued investment for growth that is part of the five-year strategic development plan for the business.
The progress of the five-year strategy continues in line with management expectations. Diabetes and Hematology delivered steady performances in the first half, with the majority of high-volume tenders already won and scheduled to be delivered in the historically stronger H2. β-HB revenues grew by 4%, exceeding first half expectations, and overall Life Sciences continues to deliver high growth 20%, with Contract Manufacturing performing particularly well in the first half.
The Company remains on track to deliver growth at the revenue and adjusted EBITDA levels for FY 2026 in line with current market expectations2.
EKF will announce unaudited results for H1 2026 on 15 September 2026.
1 Earnings before interest, tax, depreciation and amortisation, excluding exceptional items.
² Management understands consensus revenue and Adjusted EBITDA forecasts for FY 2026 to be £54.7m and £13.6m respectively.
The person responsible for arranging the release of this Announcement
on behalf of the Company is Gavin Jones, Chief Executive Officer.
|
EKF Diagnostics Holdings plc |
|||
|
Julian Baines, Executive Chair |
via Walbrook PR |
||
|
Gavin Jones, Chief Executive Officer |
|
||
|
Helen Jones, Chief Financial Officer
|
|
||
|
Singer Capital Markets (Nominated Adviser & Broker) |
Tel: +44 (0)20 7496 3000 |
||
|
Jen Boorer / Russell Cook / Patrick Weaver |
|
||
|
|
|
||
|
Walbrook PR Limited |
Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com |
||
|
Paul McManus / Alice Woodings |
Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654 |
||
About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com)
EKF is an AIM-listed global diagnostics business focussed on:
|
● |
Point-of-Care analysers in the key areas of Hematology and Diabetes |
|
● |
Life Sciences services provide specialist manufacture of enzymes and custom products for use in diagnostic, food and industrial applications. |
EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing sites across the US and Germany, selling into over 120 countries world-wide.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 11 hours ago Johnson Matthey
- 12 hours ago Galliford Try
- 12 hours ago Galliford Try
- 12 hours ago Centrica
- 13 hours ago Smith & Nephew